Whalesbook
Hemant Surgical Industries Lands Landmark ₹264 Crore Government Order
Mumbai, India – Hemant Surgical Industries Limited, a player in the medical equipment and supplies sector, has announced a significant new business win: a purchase order valued at a substantial ₹264.33 crore from the Central Medical Service Society (CMSS). CMSS, a key government entity operating under the Ministry of Health and Family Welfare, has placed this order for the supply of critical medical equipment, including a Flat Panel Detector with batteries, a router, and an X-ray Generator.
This order represents a transformative moment for Hemant Surgical, significantly dwarfing its previous financial performance. For the fiscal year ending March 2023, the company reported total revenues of approximately ₹111.5 crore and a net profit of around ₹7.7 crore. While preliminary figures for FY25 suggest revenues around ₹106.64 crore and a net profit of ₹8.04 crore, the new CMSS order alone is more than two and a half times its annual revenue. The company has agreed to begin interim supplies, highlighting the national importance of the project, with the full execution of the order planned in stages by September 30, 2026, pending final commercial terms.
The Backstory: A Series of Government Wins
This is not the first major government contract for Hemant Surgical. In September 2025, the company had announced securing an order worth ₹82.89 crore from the same CMSS for the supply of ultraportable handheld X-ray machines. These consistent wins from government bodies underscore Hemant Surgical's growing capabilities and its importance in supplying critical medical infrastructure to public healthcare facilities across India. The medical device market in India is a rapidly expanding arena, valued at an estimated USD 6.8 billion in FY24 and projected to reach USD 50 billion by 2030, driven by increased healthcare spending and government initiatives like 'Make in India'.
The Risk Report: Navigating Regulatory Waters
While Hemant Surgical Industries has demonstrated growth and secured significant orders, its history includes a past regulatory challenge. In 2021, the company was involved in a customs dispute concerning imported used haemodialysis machines. The Customs Department had proposed confiscation and penalties, alleging violations related to hazardous waste. However, the Bombay High Court later set aside the customs order, ruling in favour of Hemant Surgical, and allowed the refund of a redemption fine. This incident highlights the complexities of import regulations but does not indicate any current fraud or systemic governance failure.
Financial Deep Dive & Outlook
The ₹264.33 crore order is expected to dramatically impact Hemant Surgical's revenue streams over the next two financial years. Management's ability to execute this large order efficiently, manage working capital, and maintain quality will be crucial. The company previously reported revenue growth of 5.4% in FY23 and raised approximately ₹61.53 crore through a preferential allotment in November 2025, intending to fund expansion and working capital. This new order provides a strong impetus for that expansion.
Peer Comparison & Big Picture
The Indian medical equipment market is highly competitive, featuring both multinational corporations and domestic manufacturers. Companies like Opto Circuits (India) Ltd., Poly Medicure Ltd., and Syringe India Ltd. operate in related segments. While specific direct competitors for this exact type of X-ray generator and detector supply aren't detailed, the overall trend shows increasing domestic production encouraged by government policies like the Production Linked Incentive (PLI) scheme. Hemant Surgical's consistent wins from CMSS place it favourably within the government procurement landscape, potentially giving it an edge over peers in securing such large-scale public tenders.
This substantial order from CMSS positions Hemant Surgical Industries as a key supplier for India's public health infrastructure, with the potential for significant revenue growth and market share expansion in the coming years. Investors will be watching closely for the execution progress and financial performance impact.